Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma
Related Experiment Video
Updated: Apr 7, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
M Bryan Warf1, Placede G Fosso1, Elisha Hughes1
1Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
Aims:
The aim of these studies was to validate the analytical performance of a cell cycle progression (CCP) gene signature that provides prognostic information for early stage lung adenocarcinomas.
Materials & Methods:
Formalin-fixed paraffin-embedded (FFPE) lung resections were evaluated by quantitative RT-PCR for the expression of 31 target and 15 housekeeper genes comprising the CCP score.
Results:
The signature had a standard deviation (SD) of 0.06 score units and a dynamic range spanning CCP scores between -13 and 14. The average amplicon efficiencies for target and housekeeper genes were 107% and 105%, respectively. All but one amplicon had a SD <0.5 CT.
Conclusion:
These studies demonstrate that the gene signature is robust and reproducible, making it suitable for use in a clinical setting.
More Related Videos
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
08:49Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016